Asthma Clinical Trial
To determine the natural history, etiology, and interrelationships of emphysema, chronic bronchitis, asthma, and related airways obstructive diseases. Also, to determine the relationship of acute lower respiratory tract illnesses in infants and children to the development of subsequent chronic lung disorders.
BACKGROUND:
The Tucson Epidemiology Study of Chronic Obstructive Lung Diseases had been supported by the
Specialized Center of Research (SCOR) mechanism since 1971. The SCOR mechanism was
instituted to advance basic knowledge and to generate the most effective techniques and
methods of clinical management and prevention.
In 1970, the chronic obstructive lung diseases (COLD) of bronchitis, emphysema, and asthma
were the tenth leading cause of death in the United States. At that time United States
mortality from emphysema had been increasing at the rate of 20-25 percent per year. In 1969
the death rate for COLD as a whole was 15.6 per 100,000 and that rate was considered to be
only about one-half of all those deaths in which COLD was either an underlying or an
important contributory cause. By 1986 COLD had risen to be the fifth leading cause of death
in the United States with a death rate of 31.3 per 100,000.
By 1972 many prevalence surveys had been conducted in the United States and abroad on
specific subgroups of populations. At that time, most longitudinal studies were limited in
the scope of examinations conducted, dealt with restricted age groups, and conducted few
studies of familial concordance of diseases. The Tucson study was designed to include a wide
age span, family units, and a variety of features relating to reversible or irreversible
obstructive lung disease.
Studies have provided evidence relating acute lower respiratory tract illnesses in the first
few years of life to the development of chronic lung disease in later life. Epidemiologic
studies have demonstrated that geographic areas with high morbidity and mortality rates due
to chronic obstructive lung disease among adults are also likely to show a high incidence of
respiratory illness among children. A number of risk factors may be associated with lower
respiratory tract illness in children. Some studies suggested that familial or genetic
factors may predispose certain children to respiratory disorders early in life. Family size,
viral and bacterial infections, allergic reaction, air pollution, gas stoves, formaldehyde,
and passive smoking have all been implicated. Research was needed on the interrelationships
of potential risk factors and lower respiratory tract infections in producing chronic
respiratory disease.
DESIGN NARRATIVE:
The Tucson Study of Chronic Obstructive Lung Diseases was longitudinal in design. By 1986,
nine surveys had been completed on 70 percent of the same population surveyed at baseline in
1972. Data collected in the surveys included basic standardized questionnaires and maximum
expiratory flow volume (MEFV) curves using the same pneumotachograph equipment. Additional
questionnaires were included on smoking, medical and occupational history, socio-economic
characteristics, and height and weight measurements. Blood was sampled for studies of
alpha-1-antitrypsin level. Several surveys included allergy skin testing, blood pressure,
and anthropometric measurements. Studies of the 504 out-migrants continued since 1982.
Twelve surveys were planned to insure a follow-up of at least 15 years on all adults.
Funding represented approximately 26 percent of the dollars of the Specialized Center of
Research in Chronic Diseases of the Airways (P5OHL14136) used to support the Tucson Study.
Childrens' Respiratory Study of Tucson was also longitudinal in design and assessed the role
of infectious, physiologic, immunologic, allergic, genetic, environmental, and familial
factors in the development of acute and chronic lower respiratory tract illnesses in
childhood. Enrollment of the study population and their families occurred between May 1980
and October 1984. Healthy infants were enrolled within a few days of birth, at which time
baseline data were collected. Cord and 9-month bloods were evaluated for a number of
immunologic tests. In the first few months of life, prior to any lower respiratory tract
illnesses, a subset of the population underwent pulmonary function testing. During lower
respiratory tract illness, specimens were obtained for viral, chlamydial, and mycoplasma
cultures and tests. Environmental factors evaluated included passive smoking, number of
siblings, overcrowding, and air pollution. Data collection was continued on the children and
their family members over the years.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|